PMID- 20156510
OWN - NLM
STAT- MEDLINE
DCOM- 20100709
LR  - 20151119
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 71
IP  - 5
DP  - 2010 May
TI  - Prognostic relevance of soluble human leukocyte antigen-G and total human 
      leukocyte antigen class I molecules in lung cancer patients.
PG  - 489-95
LID - 10.1016/j.humimm.2010.02.015 [doi]
AB  - The aim of this study was to determine the prognostic significance of soluble 
      human leukocyte antigen (HLA) class I (sHLA-I) and HLA-G molecules in lung cancer 
      patients. A total of 23 small-cell lung cancer (SCLC) and 114 non-small-cell lung 
      cancer (NSCLC) patients, including 55 adenocarcinoma, 46 squamous cell carcinoma 
      (SCC), and 13 patients with undifferentiated carcinoma, were prospectively 
      enrolled. Levels of sHLA-G and sHLA-I were analyzed by specific enzyme-linked 
      immunosorbent assay. Median levels of sHLA-G and sHLA-I were significantly 
      increased in patients compared with controls (34 ng/ml [3.6-160] vs 14 ng/ml 
      [0-98], p < 0.0001; 2580 ng/ml [749-5770] vs 1370 ng/ml [274-2670], p < 0.0001, 
      respectively). Regarding the different subgroups, patients with NSCLC or SCLC 
      showed increased sHLA-I levels, whereas sHLA-G was exclusively elevated in NSCLC, 
      especially in patients with SCC. Patients with sHLA-I<2800 ng/ml (p = 0.008) or 
      sHLA-G<40 ng/ml (p = 0.073) showed prolonged overall survival (OS). Using these 
      cut-offs in patients with SCC, a pronounced prognostic significance for sHLA-G (p 
      = 0.003) and sHLA-I (p = 0.004) was observed for the prediction of OS. Here, 
      multivariate analysis confirmed sHLA-G and sHLA-I in addition to disease stage as 
      independent prognostic factors. The prognostic power was further enhanced by 
      combining the two factors and comparing the OS of patients with low sHLA-I and 
      low sHLA-G against the remaining ones. In conclusion, plasma levels of sHLA-G and 
      sHLA-I are potent predictors for OS in lung cancer patients.
CI  - Copyright 2010 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Schutt, Philipp
AU  - Schutt P
AD  - Department of Medicine (Cancer Research), West German Cancer Center, University 
      of Duisburg-Essen, Essen, Germany. philipp.schuett@uni-due.de
FAU - Schutt, Birgit
AU  - Schutt B
FAU - Switala, Magdalena
AU  - Switala M
FAU - Bauer, Sebastian
AU  - Bauer S
FAU - Stamatis, Georgios
AU  - Stamatis G
FAU - Opalka, Bertram
AU  - Opalka B
FAU - Eberhardt, Wilfried
AU  - Eberhardt W
FAU - Schuler, Martin
AU  - Schuler M
FAU - Horn, Peter A
AU  - Horn PA
FAU - Rebmann, Vera
AU  - Rebmann V
LA  - eng
PT  - Journal Article
DEP - 20100310
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Biomarkers, Tumor/*blood/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HLA Antigens/*blood
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/*blood
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*blood/*immunology/mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
EDAT- 2010/02/17 06:00
MHDA- 2010/07/10 06:00
CRDT- 2010/02/17 06:00
PHST- 2009/11/23 00:00 [received]
PHST- 2010/01/27 00:00 [revised]
PHST- 2010/02/09 00:00 [accepted]
PHST- 2010/02/17 06:00 [entrez]
PHST- 2010/02/17 06:00 [pubmed]
PHST- 2010/07/10 06:00 [medline]
AID - S0198-8859(10)00058-3 [pii]
AID - 10.1016/j.humimm.2010.02.015 [doi]
PST - ppublish
SO  - Hum Immunol. 2010 May;71(5):489-95. doi: 10.1016/j.humimm.2010.02.015. Epub 2010 
      Mar 10.